| EULAR definition of difficult-to-treat rheumatoid arthritis G Nagy, NMT Roodenrijs, PMJ Welsing, M Kedves, A Hamar, ... Annals of the rheumatic diseases 80 (1), 31-35, 2021 | 315 | 2021 |
| EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis G Nagy, NMT Roodenrijs, PMJ Welsing, M Kedves, A Hamar, ... Annals of the rheumatic diseases 81 (1), 20-33, 2022 | 159 | 2022 |
| Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis K Gulyás, Á Horváth, E Végh, A Pusztai, Á Szentpétery, Z Pethö, A Váncsa, ... Clinical rheumatology 39, 167-175, 2020 | 71 | 2020 |
| Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations … NMT Roodenrijs, A Hamar, M Kedves, G Nagy, JM van Laar, ... RMD open 7 (1), e001512, 2021 | 63 | 2021 |
| Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis E Végh, G Kerekes, A Pusztai, A Hamar, S Szamosi, A Váncsa, L Bodoki, ... Rheumatology international 40, 427-436, 2020 | 39 | 2020 |
| Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis A Hamar, Z Szekanecz, A Pusztai, M Czókolyová, E Végh, Z Pethő, ... Osteoporosis International, 1-9, 2021 | 31 | 2021 |
| Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat … NMT Roodenrijs, M Kedves, A Hamar, G Nagy, JM van Laar, ... RMD open 7 (1), e001511, 2021 | 22 | 2021 |
| Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients Á Horváth, E Végh, A Pusztai, Z Pethő, A Hamar, M Czókolyová, ... Arthritis Research & Therapy 21, 1-10, 2019 | 19 | 2019 |
| Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis E Balogh, A Pusztai, A Hamar, E Végh, S Szamosi, G Kerekes, ... Clinical Immunology 199, 47-51, 2019 | 15 | 2019 |
| Changes of metabolic biomarker levels upon one-year anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis: associations with vascular pathophysiology M Czókolyová, A Pusztai, E Végh, Á Horváth, A Szentpéteri, A Hamar, ... Biomolecules 11 (10), 1535, 2021 | 12 | 2021 |
| Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone … A Hamar, Z Hascsi, A Pusztai, M Czókolyová, E Végh, Z Pethő, K Gulyás, ... RMD open 7 (3), e001804, 2021 | 11 | 2021 |
| Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: a metabolomic approach B Soós, A Hamar, A Pusztai, M Czókolyová, E Végh, S Szamosi, Z Pethő, ... Frontiers in medicine 9, 1011734, 2022 | 10* | 2022 |
| Biosimilars vs originators: Are they the same? P Sarzi-Puttini, D Marotto, R Caporali, M Galeazzi, F Atzeni, A Hamar, ... Autoimmunity Reviews 18 (12), 102404, 2019 | 10 | 2019 |
| Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis S Póliska, T Besenyei, E Végh, A Hamar, A Pusztai, A Váncsa, N Bodnár, ... Arthritis Research & Therapy 21, 1-11, 2019 | 8 | 2019 |
| Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis: Effects of 1-year antitumor necrosis factor-α therapy A Pusztai, A Hamar, Á Horváth, K Gulyás, E Végh, N Bodnár, G Kerekes, ... The Journal of Rheumatology 48 (6), 821-828, 2021 | 7 | 2021 |
| Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations … NMT Roodenrijs, A Hamar, M Kedves, G Nagy, JM van Laar, ... | 7 | |
| Angiotensin converting enzyme activity in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients B Soós, M Fagyas, Á Horváth, E Végh, A Pusztai, M Czókolyová, ... Frontiers in Medicine 8, 785744, 2022 | 6 | 2022 |
| Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients B Juhász, K Gulyás, Á Horváth, E Végh, A Pusztai, Á Szentpétery, Z Pethő, ... BMC Musculoskeletal Disorders 22, 1-9, 2021 | 6 | 2021 |
| Effects of one-year anti-TNF-α therapy on biomarkers of angiogenesis and functional vascular parameters in arthritides E Balogh, E Végh, G Kerekes, A Pusztai, A Hamar, K Hodosi, S Szamosi, ... Rheumatol Orthop Med 4, 1-8, 2019 | 6 | 2019 |
| Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician Z Szekanecz, MH Buch, C Charles-Schoeman, J Galloway, ... Nature Reviews Rheumatology, 1-15, 2024 | 4 | 2024 |
